Study S001581

Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00614120
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 929
Start: 2008-01
Primary completion: 2009-02
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride; DRUG:metformin
Results posted: TRUE

Registered primary outcomes

Change in Glycosylated Haemoglobin A1c (HbA1c) [week 0, week 16]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023483	Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Jensen TM, Diabetes care	2015	Systematic review	PMID 25504028 DOI	registry reference RESULT:25504028
R0023657	Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea. Ingwersen SH, Diabetes research and clinical practice	2015	Randomized trial	PMID 25684604 DOI	registry reference RESULT:25684604
R0020069	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Alves C, Diabetes research and clinical practice	2012	Systematic review	PMID 23010561 DOI	registry reference RESULT:23010561
R0017232	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Buse JB, The Journal of clinical endocrinology and metabolism	2011	Other trial	PMID 21450987 DOI	cites ClinicalTrials.gov:NCT00614120; registry reference DERIVED:21450987
R0027084	Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Yang W, Diabetes, obesity & metabolism	2011	Randomized trial	PMID 21114607 DOI	registry reference RESULT:21114607